REMEDY : BNSSG referral pathways & Joint Formulary

BNSSG Adult Joint Formulary
Home > Formulary : Adult > Recent Decisions > 2012 >

Decisions 2nd October 2012

At the meeting on 2nd October 2012 the following additions/changes to the formulary were agreed:



  • Approved, TLS Red for patients who have suffered a relapse of C. difficile infection, or for those patients with a first C. difficile infection who are taking concurrent antibiotics which they cannot stop.


  • Approved for use at NBT in addition to UHB, TLS Red for the treatment of hypercalcaemia in primary hyperparathyroidism.


  • Approved for use at NBT in addition to UHB, TLS Red. A surgical glue.


  • Approved for the treatment of melasma, TLS Red, for Consultant Dermatologist use only. 

Mesalazine (Octasa®)

  • Approved, as our first line Mesalazine brand for new uncomplicated patients (400mg and 800mg tablets), TLS Green. Mezevant® XL and Mesren® to be removed from formulary

Perampanel (Fycompa®)

  • Approved for the adjunctive treatment in the management of partial onset seizures with or without secondary generalisation, TLS Red

Amantadine in MS

  • Approved for the use in MS patients with fatigue, TLS amber.

Tobramycin (TOBI Podhaler®)

  • Deferred until results of contract price negotiation on nebulised tobramycin is known


  • Approved as the recommended choice for the treatment of heparin induced thrombocytopenina, TLS Red. Danaparoid is now an alternative and Lepirudin removed.

Ulipristal (Esmya®)

  • Approved for the treatment of uterine firboids, TLS Red


New/updated Shared Care Protocols

  • Disease Modifying Antirheumatic drugs - Azathioprine, Leflunomide, Methotrexate, Sodium aurothiomalate, Penicillamine, Hydroxychloroquine.  All updated.
  • Acamprosate
  • Valproic acid
  • Colistimethate for the use in chronic respiratory patients (adult non-Cystic Fibrosis)
  • Hepatitis B vaccination in renal patients
  • Stalevo®
  • Ropinirole
  • Lanthanum
  • Naltrexone for alcohol withdrawl (TLS Change from Red to amber)
  • Naltrexone for opioid withdrawl


Other decisions/changes

  • Tafluprost added (for patients who need preservative free eye drops in the treatment of glaucoma)
  • Ivabradine license extension for use in patients with heart failure